SEC Filing Summary: Stellar Biotechnologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed on March 23, 2016, by Stellar Biotechnologies, Inc., a company incorporated in British Columbia, Canada, with principal executive offices in Port Hueneme, California. The filing reports events occurring on March 23, 2016, regarding the company's status on the TSX Venture Exchange.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and exchange listing status rather than financial performance.
Material Changes
- Voluntary Delisting Application: The Company announced it has applied for the voluntary delisting of its common shares from the TSX Venture Exchange.
- Investor Disclosure: The Company posted a "TSX-V Voluntary Delisting FAQ" on its investor relations website to address shareholder inquiries regarding the delisting process.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, future outlook, or specific risk factors beyond the implications of the voluntary delisting. The primary event is the administrative action to remove the company's shares from the TSX Venture Exchange.
Key Facts for Investor Verification
- Verify the current trading status of Stellar Biotechnologies, Inc. shares following the delisting application.
- Review the "TSX-V Voluntary Delisting FAQ" on the company's website for details on the timeline and reasons for delisting.
- Confirm if the company intends to list on an alternative exchange or trade over-the-counter (OTC).
- Note that the filing references a press release (Exhibit 99.1) for the official announcement details.